RE: Blackman Coulter3 Apr 2022 11:18
The interesting thing to me is how David Budd suggested in the presentation that now they had made and designed this test , the next ones are really just an alteration of this one. Aiming it at the different gene/segment of gene. All the heavy work has been done. The process has been designed built and tested on a machine which has 20 years worth of development and trials ect.
That makes the potential huge for a large pharma with the ability to fund multiple test developments at a time. imagine 5,6,7 or more tests a year going into the approval stages. Soon a huge portfolio of tests.
The potential is huge. I would be expecting a least a nibble from a large Biotech company, personlize medicine is the way forward now.
next up star trek medical scanners :)